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PThe Left Main Facts: Faced, Spun, But Alas Too Few
Jeff Brinker, MD, FACC
Baltimore, Maryland
Bypass surgery has been shown to prolong life in patients with significant left main stenosis compared with
medical therapy and is the current standard of care. Recent registry data suggest that stenting may offer
intermediate-term results similar to surgery, although with a greater need for repeat revascularization. Drug-
eluting stents appear to improve the outcomes of stenting. Over 20% of patients with left main disease currently
receive stents, and there is need for ongoing randomized controlled trials to validate this approach. It is essen-
tial that such patients receive balanced counseling as to revascularization options. (J Am Coll Cardiol 2008;51:
893–8) © 2008 by the American College of Cardiology Foundation

































Ft is, at times, both interesting and disconcerting to observe
he dialectic process unfold in the medical literature. One
urrent battleground is a small, averaging a bit over a
entimeter in length (1), but critically located segment of
oronary artery. In itself the debate over revascularization
or left main (LM) disease serves as a mini-conflict in the
ong-continuing cold war over the “best” approach for
schemic vascular disease. It has been termed by some the
last bastion” of bypass surgery while others consider it the
final challenge” to percutaneous coronary intervention
PCI). Hyperbole aside, this segment is unique in several
spects: it arises directly from the aorta and thus exhibits
issue and structural properties at its ostium, which differ
rom those in the rest of its course; it is subject to a number
f unusual disease processes in addition to atherosclerosis,
ncluding iatrogenic injury; it serves as the primary thor-
ughfare for left ventricular blood flow, the interruption of
hich, even for a short time, can be potentially catastrophic;
nd, although it is relatively large in diameter, it terminates
s a disease-prone bifurcation/trifurcation from which the
maller caliber left anterior descending (LAD), circumflex,
nd occasionally the intermediate branches arise. Significant
M stenosis occurs in only about 6% of patients undergoing
iagnostic coronary angiography (2); however, recent evi-
ence suggests a familial aggregation (3). The presence of
ignificant LM disease signals a poor prognosis with a
-year survival as low as 37% depending on the degree of
tenosis, left ventricular function, and associated coronary
isease (4). The importance of coronary artery bypass
rafting (CABG) over medical therapy for LM disease was
stablished a quarter century ago by observational and
andomized controlled trials (5–7). The magnitude of sur-
ical benefit was influenced by both the degree of LMs
rom The Johns Hopkins Hospital, Baltimore, Maryland.
Manuscript received October 10, 2007; accepted October 24, 2007.tenosis and left ventricular function. The operative mortal-
ty was also associated with these factors as well as the
mmediacy of the need for surgery, gender, and left coronary
ominance (8). The survival benefit of CABG extended
nly to the higher-risk subgroups of patients with symp-
omatic coronary disease.
Lesions of the LM vary anatomically and functionally in
ays that might influence the choice of revascularization
nd should not be considered as a single class: isolated LM
isease is infrequent, accounting for only 6% of patients
ndergoing surgery with an LM stenosis (9); obstructive
isease is not evenly distributed over the course of the LM,
ith the distal portion involved in about two-thirds of the
ases, ostial lesions occurring in about one-quarter, and the
emainder localized to the shaft (10); and the clinical import
f the LM is derived from its functional distribution, which
ay be influenced by previously placed bypass graft(s), prior
eft anterior descending or circumflex branch occlusion, the
ize and distribution of the right coronary artery, or by the
nomalous origin of a coronary artery.
There are few individuals as well acquainted with the LM
s are the interventionalists who traverse this region on a
egular basis and, on occasion, contribute to the develop-
ent of stenosis (11) or cause acute injury (12) in it. Efforts
t PCI of LM disease began with Grüntzig et al. (13), who
escribed the ease as well as the risk of dilating the left main
n his initial series of patients reported in 1979. Despite his
autions against angioplasty in this group, interventionalists
ave found it difficult to resist the temptation. The initial
eport of the National Heart, Lung, and Blood Institute
ngioplasty registry (14) describes 19 patients having LM
alloon angioplasty with a procedural success rate of 68%
the highest of any other target site) and no procedural
ortality. The death of 2 patients after hospital discharge,
owever, cast doubt about the safety of this procedure.
urther the experience with balloon dilation for LM steno-
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The Main Facts March 4, 2008:893–8acute and long-term risk, espe-
cially in patients with acute isch-
emic presentations and unpro-
tected LM lesions (15). The
introduction of bare-metal stents
(BMS) addressed some of the
concerns about procedure stabil-
ity and restenosis but was still
associated with a high restenosis
rate, especially in bifurcation le-
sions, and high post-discharge
mortality (16). Protected LM le-
sions, however, could be treated
with acceptable results (17).
Thus, until recently the generally
accepted utility of LM PCI has
been relegated to situations in
hich the LM is “protected” by a previously placed graft in
branch vessel, the dependent distribution is small, the
urgical risk is prohibitive, or the need emergent. Introduc-
ion of drug-eluting stents (DES) has been followed by
eports of favorable experiences with these devices in un-
rotected LM disease, and the technique has been extended
o patients who would be otherwise good surgical candi-
ates. It is estimated that PCI is now performed in 26% of
M patients in Europe and 21% in the U.S. (18). In this
ssue of the Journal, Taggert et al. (19) take interventional-
sts to task over the appropriateness of PCI for LM
pecifically and for surgically approachable high-risk coro-
ary disease in general. This perspective deserves careful
eading and some comment.
The challenges offered by Taggert et al. (19) are summa-
ized as follows: 1) interventionalists influence the therapy
f patients with multivessel and LM disease without pro-
iding a balanced discussion of CABG; 2) published evi-
ence and existing guidelines support the superiority of
ABG for these conditions; 3) the current root cause
avoring aggressive PCI is misguided enthusiasm that DES
ave leveled the playing field with surgery by eliminating
he major shortcoming (restenosis) of balloon angioplasty
nd BMS; this is ill founded, as the risk of stent thrombosis
ST) may outweigh any advantage; 4) the very nature of LM
isease is ill-suited for stenting; 5) advances in surgical
echnique including bilateral internal thoracic arterial grafts
ave overcome limitations of saphenous vein grafts; and 6)
he ethics of a randomized controlled trial comparing
ABG with DES for LM disease are questionable because
here is a lack of equipoise between the proven “standard of
are” and DES.
Consideration of these points might begin with the
cceptance of 2 axioms. First, there is no perfect long-
asting revascularization procedure; both grafts and stents
ay fail early or over time, and new disease may develop
roximal or distal to the site of revascularization. Second,
raditional heart surgery involves considerable physiological
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
DES  drug-eluting stent(s)
ITA  internal thoracic
artery
LAD  left anterior
descending coronary artery




ST  stent thrombosisnsult and “up front” risk of significant adverse events, Bncluding an operative mortality of between 1% and 4% and
prolonged recovery. Patients are reluctant to face these
isks if given a less invasive, albeit imperfect, option. They




t is true that interventionalists do not routinely suggest a
urgical consultation to patients they feel are candidates for
CI. The majority of such patients are of low to moderate
isk, the procedural success rates are high, acute complica-
ion rates are low, and this approach is widely considered
ustifiable given patient preference, the ad-hoc nature of
ost procedures, and the logistical demands of all involved.
or high-risk nonemergent patients, however, it would be
n the best interests of all to have an inclusive team approach
o ensure that the patient and family are well informed as to
herapeutic options. Although interventionalists might con-
ider themselves capable of presenting an even-handed
iscussion of both PCI and CABG, the perception among
any of our surgical colleagues is that a conflict of interest
s inherent in such an approach. Interestingly, in a survey of
ttitudes of interventionalists toward LM PCI, 48% con-
ulted a surgeon in all potential LM PCI, 48% did so in
elected patients, and only 4% thought that a surgeon
hould not be involved in the process. Only 19% thought
hat LM PCI should be offered to patients who were good
urgical candidates; however, 38% said that is was appro-
riate to do the procedure in patients who request it (20).
ABG Versus PCI for Multivessel Disease
he contention that CABG is superior to PCI for mul-
ivessel disease is arguable. The paper by Hoffman et al. (21)
s a meta-analysis consisting of 8 randomized trials spanning
he transition from balloon angioplasty to stenting, with
nly 35% of the total receiving stents. There was no survival
ifference at 1 and 3 years (in which stented patients were
epresented), but there was a difference at 5 and 8 years
avoring CABG; these data, however, were derived from the
arly studies that did not include stents. Hannan et al. (22)
nalyzed data from the New York State CABG and PCI
egistries (pre-DES), showing better survival with the
ormer. This is an important observation, although it suffers
he limitations of a nonrandomized retrospective study. The
ong-term results of 2 pre-DES randomized trials are
vailable: ERACI II (Argentine Randomized Trial of Cor-
nary Angioplasty With Stenting Versus Coronary Bypass
urgery in Patients With Multiple Vessel Disease) (23) and
RTS (Arterial Revascularization Therapies Study) (24)
how CABG and PCI to be equivalent in infarct-free
urvival. Surgery, however, has been consistently shown to
e associated with a lessened need for revascularization.
ver the 5-year follow-up of ARTS and ERACI II, the
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March 4, 2008:893–8 The Main Factsimes more frequently; however, these studies were per-
ormed with BMS. At the 10-year follow-up report of the
ARI (Bypass Angioplasty Revascularization Investigation)
rial comparing balloon angioplasty with CABG, revascu-
arization had been performed in 77% of the PCI group and
0% of the CABG patients with no difference in survival
etween the 2 arms (25). Although restenosis is a significant
isadvantage of PCI, its specific association with infarction
nd death has not been emphasized but rather bundled with
he overall PCI risk. The potential to reduce the incidence
f restenosis has refocused attention on its associated 10%
isk of myocardial infarction and 0.7% risk of death (26).
lthough the risk of restenosis may not be considered a
ompelling reason to favor CABG over PCI as the initial
pproach to multivessel disease, it becomes a more
isturbing shortcoming in the LM, where the conse-
uences may be more ominous. A further consideration,
hich remains uncertain, is whether the risk of CABG
or PCI restenosis is increased (27,28).
nfluence of DES on PCI
he introduction of DES has reduced the incidence of
estenosis and target lesion revascularization compared with
hat seen with BMS without evidence thus far of the
nticipated increase in infarct-free survival in patients with
ultivessel disease (29). The beneficial effects on the rest-
notic process, however, extend across a wide range of
atient subgroups including diabetic patients and have led
o more aggressive PCI (30) as well as a decrease and change
n the population of patients going to CABG who are now
lder and sicker (31). Whereas the adverse event rate for
ES is increased in “off-label” compared with “on-label”
pplication, this is not true for all such applications (32,33),
or is it clear how much “off-label” risk is related to clinical
ubstrate as opposed to stent type because there is a paucity
f controlled studies comparing BMS or CABG with
off-label” DES use.
There has been concern that the current generation of
ES may prevent or delay protective endothelium from
overing the stent and, hence, increase the risk of ST.
lthough the incidence of ST in the early post-implant
eriod is no different from that of BMS, there appears to be
continued risk with DES at a rate of 0.6 per year (34) for
n as yet undefined duration. The interventional commu-
ity, at first skeptical of an increased risk of late ST, has now
ccepted this and argues that a favorable tradeoff exists
etween a small risk of ST and a large reduction in
estenosis. Whether the incidence of ST is further increased
n “off-label” use is uncertain. The role of dual antiplatelet
herapy in preventing ST is emphasized, and extension of
he labeled duration of this regimen to 12 months advocated
35). Many of us, however, tend to prolong clopidogrel well
eyond this period, a strategy that would seem prudent for
ES placed at critical sites such as the LM. Because
remature cessation of antiplatelet therapy has serious ponsequences, expectation of bleeding complication or need
or noncardiac surgery within a year of implant argues
gainst placing DES, especially in an unprotected LM.
uitability of the LM for PCI
here are studies suggesting that distal LM disease is not
ell dealt with by PCI. Valgimigli et al. (36) found PCI to
ave twice the incidence of death or myocardial infarction in
istal LM disease compared with disease limited to the
stium or shaft. This appeared to be independent of
hether a single or bifurcation stenting strategy was used.
erial surveillance angiography in a cohort of LM PCI
atients with primarily bifurcation stenting revealed a 38%
ncidence of restenosis requiring revascularization. Most
estenosis was focal and located at the orifice of the
ircumflex artery, thus lending itself to repeat PCI. Al-
hough the incidence of death in this group was low (2%),
cute ST occurred in 2 patients (37). In contradistinction to
hese studies, Chieffo et al. (38) have reported quite favor-
ble results for PCI not involving the left main bifurcation.
n this group followed for about 2.5 years, there was an
ll-cause death rate of 3.4%. Revascularization was neces-
ary in 5.4% of patients, but only 1 (0.9%) had LM
estenosis.
Further data suggest that distal LM disease may be
easonably approached by PCI. In a single-center registry
omparing PCI and CABG outcomes at 1 year, there was
o difference in the composite end point of death, stroke,
yocardial infarction, and revascularization. Distal LM
isease was present in 81% of the PCI group, three-quarters
f which received stenting to both branches. Repeat revas-
ularization was performed in 20% of the PCI (one-half of
hich was clinically driven) and 5% of the CABG patients
39). Other studies using primarily a single stent DES
pproach to patients with distal disease demonstrated even
ower rates of revascularization (40,41).
High-risk patients for CABG might be considered at
ncreased risk for PCI as well. Lee et al. (42) compared
utcomes of high-risk patients receiving DES (18% turned
own for surgery) with outcomes of CABG patients (Par-
onnet scores 18.3 and 13.7, respectively). Distal LM
isease was present in 60% of DES patients, and bifurcation
tenting was performed in two-thirds of these. The esti-
ated major adverse cardiac and cerebral vascular event-free
urvival at 6 months was 89% for DES and 83% for CABG.
reedom from revascularization at 1 year was estimated to
e 95% for CABG and 87% for PCI (42). Other reports by
igliorini et al. (43) and Palmerini et al. (44) of high-risk
atients, the majority of which had bifurcation disease,
eveal results similar to CABG except for a more frequent
eed for repeat revascularization. Thus, PCI with DES has
emonstrated acceptable short- and intermediate-term sur-
ival results compared with those seen with CABG, even in
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The Main Facts March 4, 2008:893–8The Bologna registry (45) provides interesting data that
elp provide some perspective for comparison of CABG
nd PCI. Patients with unprotected LM disease were
reated with either CABG or PCI in accordance with
hysician and patient choice. The PCI group was older and
ad higher risk scores. Retrospective analysis by physician
nd surgeon revealed that 68% of the total group were
ppropriate for either PCI or CABG; 19% for CABG only,
nd 13% for PCI only. There was no difference in death or
yocardial infarction at 14 months between PCI and
ABG; however, the incidence of repeat revascularization
as higher in the PCI group, 25.5% versus 2.6% for CABG.
he cohort receiving DES (60% of PCI) had a 22%
ncidence of revascularization. This was thought to be
elated to the high incidence of bifurcation stenting as well
s routine surveillance angiography resulting in the detec-
ion and treatment of lesions, 63% of which were asymp-
omatic. Over 50% of the patients had associated multivessel
isease with complete revascularization achieved equally in
oth groups. Outcome was related to pre-procedural risk
ssessment: patients deemed good for surgery had equally
ood long-term survival with either CABG or PCI (3.3%
nd 3.5%, respectively), whereas poor CABG candidates
ad 18.1% and 18.8% mortality, respectively.
urability of CABG
f ST is the Achilles heel of DES, the saphenous vein offers
similar frailty for the surgeon. As many as 7% of these
rafts may occlude within 2 weeks of surgery (46). At 1-year
ost-bypass 12% to 20% of the grafts are occluded, and this
umber approaches 50% at 10 years (47). Because the
lacement of a graft tends to accelerate upstream disease
48) and its progression to complete occlusion (49), a
ubsequent graft occlusion might render PCI more difficult
r impossible. We find that 25% of all PCI at Johns
opkins Hospital is performed in patients who have had a
rior bypass. Although internal thoracic arterial (ITA)
rafts have a greater durability, 1.3% are occluded and 8%
arrowed by 50% within 2 weeks of surgery (50); the
atency rates at 1 and 5 years are 93% and 88%, respectively
51). Although there have been reports of good results with
ilateral ITA grafting, this is not frequently performed.
ata from the Society of Thoracic Surgery suggest that
onsiderably 20% of patients receive this procedure at a
rst isolated CABG (52). At my institution, about 13% of
atients undergoing CABG for left main disease and just
nder 20% of all initial CABG procedures receive bilateral
TA grafts. The SYNTAX (Synergy Between Percutaneous
oronary Intervention With Taxus and Coronary Surgery)
un-in study cites all arterial grafting being performed in
nly 12% of patients operated on for LM and triple-vessel
isease (18). A greater consensus among surgeons on the
mportance of bilateral ITA grafts, radial arterial grafts, and
ff-pump bypass might be helpful in the design of the best
omparator to LM PCI. ylinical Trials for LM Disease
ne would agree that a randomized controlled trial of a
herapy in patients with a life-threatening illness should
ffer enrollees a reasonable chance of an equal or better
esult than does the current standard of care. It is disap-
ointing that Taggert et al. (19) suggest that a randomized
ontrolled trial of DES versus CABG might be unethical
ecause there is no equipoise between the 2 arms. This
mpugns the work of the many surgeons, physicians, and
ther professionals who have designed, approved, and are
articipating in the large, ongoing randomized trials explor-
ng this question. Equipoise is an interesting term. Who
hould be equally poised—the scientific community? Sur-
eon? Cardiologist? Subject? A significant minority of
atients with unprotected LM stenosis are currently receiv-
ng PCI as the initial revascularization procedure. It would
eem important for the wider medical community to know
hether this is a reasonable option. Equipoise is currently a
ontroversial topic among the ethicists; it would seem that
he most important ethical consideration lies with the
ubject, and his/her willingness to give “. . . an adequately
nformed, free, and unexploited consent. . .equipoise is
rrelevant” (53).
I do not know whether the randomized trials will dem-
nstrate a broadened role for PCI in LM disease or not;
erhaps that is the greatest endorsement for their perfor-
ance. My guess is, however, that the trials will help to
dentify clinico-anatomical subgroups that do better with
ne or the other revascularization procedure as well as a
roup that does well with either. The term “well” is relative
n that both CABG and PCI are likely to improve over time
nd provide better long-term results. The tradeoff of re-
eated interventions for less invasivity (assuming no differ-
nce in infarct-free survival or quality of life) may be a
easonable patient preference. Taggert et al. (19) raise
mportant issues, however. Not the least of these is the
erception that interventionalists are conflicted in the advice
hey give patients with regard to revascularization therapy
nd do not provide an opportunity for the surgeon to
articipate in the counseling process. The role of commer-
ial interests in influencing interventional practice is also
elevant. We owe it to our patients and our colleagues to
ractice in an open manner that is above suspicion. As for
he current approach to LM disease, we can agree that
ercutaneous intervention is an acceptable option to CABG
or patients with a protected LM as well as select patients
ith unprotected LM, including those with emergent pre-
entation, those at very high risk for surgery, and perhaps
hose with disease limited to the ostium or shaft of the LM.
ifurcation disease is an unsettled question even with DES
nd should await the results of the ongoing randomized
rials. We have little long-term data with DES for LM and
lmost none on the outcome of repeated PCI for LM
estenosis. Optimal duration of antiplatelet therapy is not
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March 4, 2008:893–8 The Main Factseem prudent at this time to favor prolonged dual antiplate-
et therapy. Bypass surgery carries with it 3 intuitively
eneficial aspects: 2 grafts to the left system are almost
lways used providing some protective redundancy; grafts
re usually placed at sites that also protect against future
isease in the proximal LAD and circumflex systems; and
omplete revascularization is more likely to be achieved by
urgery in patients with LM accompanied by multivessel
isease. In common with the many other editorials recently
ppearing on this topic, I end with a caution that in the
bsence of definitive data to the contrary, bypass surgery
emains the standard of care for patients with unprotected
M coronary artery disease who are reasonable candidates
or surgery (54 –56).
eprint requests and correspondence: Dr. Jeffrey A. Brinker,
MSC 501, The Johns Hopkins Hospital, 600 North Wolfe
treet, Baltimore, Maryland 21287. E-mail: jbrinker@jhmi.edu.
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